← All trials
NCT05393986
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 30, 2024
- First posted
- May 27, 2022
- Last posted
- May 27, 2022
- Enrollment
- 63
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peking UniversityLead sponsor
- CARsgen Therapeutics, Ltd.Collaborator
- Peking UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.